Poolbeg Pharma PLC Announces Increase in Voting Rights

Poolbeg Pharma PLC, a leading pharmaceutical company, has recently announced a significant increase in its voting rights. The company’s voting rights have risen to 5.2% following an acquisition by Michael Kelly, who now holds 26,039,455 voting rights in the company.

The notification of major holdings was sent to Poolbeg Pharma PLC and the Financial Conduct Authority (FCA) on July 9, 2024. The acquisition of voting rights took place on July 4, 2024.

Poolbeg Pharma PLC is a non-UK issuer, and this increase in voting rights signifies a positive development for the company. The acquisition by Michael Kelly demonstrates confidence in the company’s future prospects and strategic direction.

Poolbeg Pharma PLC is known for its innovative pharmaceutical products and commitment to improving global healthcare. The company’s strong performance and dedication to research and development have positioned it as a key player in the industry.

The increase in voting rights further strengthens Poolbeg Pharma PLC’s position and provides a solid foundation for future growth and expansion. With Michael Kelly’s involvement, the company can benefit from his expertise and contribute to its continued success.

For more information, please contact:
Name: RNS
Email: rns@lseg.com
Phone: Not provided

More Posts

SWEP, a world-leading supplier of brazed plate heat exchangers (BPHEs), has unveiled its latest innovation …

Village Super Market, Inc. (NASDAQ: VLGEA) is deeply saddened to announce the passing of William …

Vicinity Motor Corp., a leading North American supplier of commercial electric vehicles, has announced the …